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Introduction
Science and knowledge progress rapidly. How to make
something out of huge data sets, large amounts of in-
formation that comes on a daily base to us through
various sources? Although the bias of hypothesis-
driven research may indeed prevent to discover the un-
usual, the downside of it is that just finding significant
correlations overflows the literature (see also the edito-
rial in this issue; [1]). This review gives some examples
of the different approaches to science, and it is up the
reader to draw conclusions.
Biology of lymphoma
Hodgkin lymphoma
The NF-kB pathway is activated in several lymphoma
types. De Oliveira et al. [2] analyzed the transcriptome
of Hodgkin lymphoma (HL) cell lines. They found that
various NF-kB subunits are recruited to a large number
of genes. Thus, NF-kB up- and downregulates gene sets
that are both distinct and overlapping and are associated
with diverse biological functions. p50 and p52 are
formed through NIK-dependent p105 and p100 precur-
sor processing in HL cells and are the predominant
DNA-binding subunits. Logistic regression analyses of
combinations of the p50, p52, RelA, and RelB subunits
in binding regions that have been assigned to genes
they regulate reveal a cross-contribution of p52 and
p50 to canonical and non-canonical transcriptomes.
These analyses also indicate that the subunit occupancy
pattern of NF-kB-binding regions and their distance
from the genes they regulate are determinants of gene
activation versus repression. The pathway-specific signa-
tures of activated and repressed genes distinguish HL
from other NF-kB-associated lymphomas and inversely
correlate with gene expression patterns in normal germi-
nal center B cells.
Paydas et al. [3] describe the profile of 377 micro
(mi) RNAs in 32 HL cases. A whole series of miRs
were differently expressed compared to normal germinal
center (GC) B cells, some with higher, others with low-
er expression, but there was no difference in miRNA
profile according to the age, sex, stage, response to
treatment, DFS, and OS. The authors conclude that we
need more studies evaluating miRNA profile and clini-
cal outcome in HL. My conclusion would be that we
need to create better hypothesis before we do analyses
that result in very large datasets.
B cell lymphomas
Gastric extranodal marginal zone lymphoma (ENMZL) is
a consequence of H. Pylori (HP) infection, but most pa-
tients who have HP gastritis will not develop a lymphoma
or carcinoma. Gossmann et al. [4] used BALB/c mice
with a gain-of-function mutation in the Plcg2 gene
(Ali5), critical for B cell maintenance, to analyze its
r o l e i n t h e d ev e l opmen t o f g a s t r i c ENMZL .
Heterozygous BALB/c Plcg2Ali5/+ and wild-type
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(WT) mice were infected with Helicobacter felis (H. felis). In
contrast to their hypothesis, Plcg2Ali5/+ mice developed
ENMZL less frequently than the WT littermates after long-
term infection of 16 months. Infected Plcg2Ali5/+ mice
showed downregulation of pro-inflammatory cytokines and
decreased H. felis-specific IgG1 and IgG2a antibody re-
sponses. These results suggested a blunted immune response
of Plcg2Ali5/+ mice towards H. felis infection. Intriguingly,
Plcg2Ali5/+ mice harbored higher numbers of CD73 express-
ing regulatory T cells (Tregs), possibly responsible for im-
paired immune response towards Helicobacter infection.
They suggest that Plcg2Ali5/+ mice may be protected from
developing gastric ENMZL as a result of elevated Treg num-
bers, reduced response to H. felis, and decrease of pro-
inflammatory cytokines. Of course, it would be interesting to
see whether such differences exist between individuals with
HP gastritis with and without ENMZL.
Cui et al. [5] investigated human gastric ENMZL with
respect to cyclooxygenase-2 (COX-2) and interleukin-32
(IL-32) expression since these have been suggested to be sig-
nificant in tumor progression and prognosis. COX-2 and IL-
32 protein expression was higher in 31 primary gastric B cell
lymphoma patients compared to 19 chronic gastritis patients,
especially so in patients who had HP-positive lymphomas; the
expression level of COX-2 was positively correlated with the
expression level of IL-32. Furthermore, COX-2 expression
was associated with an aggressive tumor type, higher number
of Ki-67 positive cells, lymph node metastasis, and advanced
stage. IL-32, and to a lesser degree COX-2, expression was
found to be correlated with frequent lymph node metastasis
and an advanced stage and poor survival.
Broutier et al. [6] use knowledge form other cancers
to study lymphoma and found a promising target for therapy.
Deleted in colorectal carcinoma (DCC) constrains tumor pro-
gression by inducing apoptosis unless engaged by its ligand
netrin-1 in breast and colorectal cancers. Using a transgenic
mouse model, they found that inhibition of DCC-induced
apoptosis is also associated with lymphomagenesis. In human
diffuse large B cell lymphoma (DLBCL), they demonstrate an
imbalance of the netrin-1/DCC ratio which suggests a loss of
DCC-induced apoptosis, either via a decrease in DCC expres-
sion in the GC subtype or by upregulation of netrin-1 in acti-
vated B cell (ABC) one. Such imbalance is also observed in
mantle cell lymphoma (MCL). Using a netrin-1 interfering
antibody, they demonstrate both in vitro and in vivo that
netrin-1 acts as a survival factor for ABC-DLBCL and MCL
tumor cells. Together, these data suggest that interference with
the netrin-1/DCC interaction could represent a promising ther-
apeutic strategy in netrin-1-positive DLBCL and MCL.
High expression of the forkhead box P1 (FOXP1) tran-
scription factor distinguishes the more aggressive ABC-
DLBCL subtype from germinal center (GC)-DLBCL subtype
and is correlated with poor outcomes. Dekker et al. [7] show
that sustained FOXP1 expression is vital for ABC-DLBCL
cell line survival. Genome-wide analyses revealed direct and
indirect FOXP1 transcriptional enforcement of ABC-DLBCL
hallmarks, including the classical NF-kB and MYD88 path-
ways. FOXP1 promoted gene expression underlying transi-
tion of the GCB-cell to the plasmablast—the transient B cell
stage targeted in ABC-DLBCL transformation—by antago-
nizing pathways distinctive of GCB-DLBCL, including that
of the GCB “master regulator,” BCL6. Cell line-derived
FOXP1 target genes that were highly correlated with
FOXP1 expression in primary DLBCL accurately segregated
the corresponding clinical subtypes of a large cohort of prima-
ry DLBCL isolates and identified conserved pathways asso-
ciated with ABC-DLBCL.
Hafsi et al. [8] show that available data can be used for new
insights. They are interested in the oncogenic transcription
factor, Yin Yang 1 (YY1), which has been reported to be
overexpressed in several malignancies. A total of 57
miRNAs that are potentially capable of targeting YY1 was
identified through in silico approaches. The search of publicly
available NHL datasets, including paired mRNA and miRNA
data highlighted a significant correlation between the expres-
sion levels of YY1 and the expression levels of a limited set of
miRNAs. They found it intriguing that, both hsa-miR-363 and
hsa-miR-200a belong to the top 20 miRNAs that were found
to be downregulated in Burkitt’s lymphoma (BL) tissue com-
pared to normal tissue. Although further validation studies are
warranted, the identification of these two miRNAs associated
with the upregulation of YY1 in BL may provide further in-
sight into the pathogenesis of this tumor and may contribute to
more personalized and targeted treatment approaches for pa-
tients with this disease. Also in this case, an approach based on
a hypothesis rather than just an interest in a specific protein
might result in more relevant data.
T cell lymphoma
Nairismägi et al. [9] used whole exome sequencing of four
cases of type II enteropathy-associated T cell lymphoma
(EATL-II) and confirmed the findings in another 42 cases by
amplicon-based deep sequencing. STAT5B was mutated in
63 % of cases, JAK3 in 35 % and GNAI2 in 24 %, with the
majority occurring at known activating hotspots in key func-
tional domains. Moreover, the STAT5B locus carried copy-
neutral loss of heterozygosity resulting in the duplication of
the mutant copy, suggesting the importance of mutant
STAT5B dosage for the development of EATL-II.
Furthermore, they show dysregulation of the JAK-STAT and
GPCR pathways by gene expression profiling. In vitro over-
expression of GNAI2 mutants led to the upregulation of
pERK1/2, a member of MEK-ERK pathway. Notably, inhib-
itors of both JAK-STAT and MEK-ERK pathways effectively
reduced viability of patient-derived primary EATL-II cells,
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indicating potential therapeutic strategies for this neoplasm
with no effective treatment currently available. This fine work
is now ready to be tested in the clinic.
A whole other approach was chosen by Hao et al. [10].
Because gain-of-function mutations in isocitrate dehydroge-
nase 1 (IDH1) can be key drivers of malignancies of the T cell
lineage, they analyzed the T cell compartment in a conditional
knock-in (KI) mouse model of mutant IDH1 and observed the
development of a spontaneous T cell acute lymphoblastic leu-
kemia (T-ALL) in these animals. The disease was transplant-
able and maintained expression of mutant IDH1. Whole ex-
ome sequencing revealed the presence of a spontaneous acti-
vating mutation in Notch1, one of the most common muta-
tions in human T-ALL, suggesting IDH1 mutations may have
the capacity to cooperate with Notch1 to drive T-ALL. To
further investigate the IDH1 mutation as an oncogenic driver
in the T cell lineage, we crossed IDH1-KI mice with condi-
tional Trp53 null mice, a well-characterized model of T cell
malignancy, and found that T cell lymphomagenesis was ac-
celerated in mice bearing both mutations. It would be interest-
ing to see whether these findings can be confirmed in human
cases.
Anaplastic large cell lymphoma (ALCL) is a peripheral T
cell lymphoma presenting mostly in children and young
adults. Malcolm et al. [11] present a mouse model of ALCL
where the malignancy is initiated in early thymocytes, before
T cell receptor (TCR) β-rearrangement. They show that a
TCR is required for thymic egress and development of periph-
eral murine tumors, yet this TCRmust be downregulated for T
cell lymphomagenesis. In keeping with this, clonal TCR rear-
rangements in human ALCL are predominantly in-frame, but
often aberrant, with clonal TCRα but no clonal TCRβ rear-
rangement, yielding events that would not normally be per-
missive for survival during thymic development. These results
explain indeed the clonality findings in many cases.
Epidemiology of lymphoma
Perry et al. [12] describe the distribution of non-Hodgkin lym-
phoma (NHL) subtypes in Southern Africa. Five expert
hematopathologists (no definition given) classified 487 con-
secutive cases of NHL using the World Health Organization
classification and compared the results to North America and
Western Europe. Southern Africa had a significantly lower
proportion of low-grade (LG) (34 %) and a higher proportion
of high-grade (HG) B cell lymphoma (B-NHL;52 %) com-
pared to Western Europe (55 and 36 %) and North America
(56 and 34 %); BL was more common, 8 versus 2 and 3 %,
most likely due to human immunodeficiency virus infection.
When the patients were divided by race, whites had a signif-
icantly higher frequency of LG (60 %) and a lower frequency
of HG B-NHL (33 %) compared to blacks (23 and 63 %),
whereas the other races were intermediate; the median ages
of whites with LG B-NHL, HG B-NHL, and T-NHL (64, 56,
and 67 years) were significantly higher than those of blacks
(55, 41, and 34 years). The authors conclude that further ep-
idemiological studies are needed to better understand these
differences, but one wonders whether access to health care
may be a critical issue here too.
It is now well known that rare cancers are common, but
hard to study. O’Suoji et al. [13] used data from the Children’s
Oncology Group Rare and Cutaneous NHL registry’s to de-
termine the pathologic, biologic, and clinical features of rare
and cutaneous pediatric NHL. In 101 lymphomas, there was a
98 % concordance between the reviewing study pathologists
and an 88% concordance between the central and institutional
pathology review, remarkably high for rare lymphomas.
Children with pediatric follicular lymphoma (FL), nodal and
extranodal primary cutaneous, primary central nervous system
lymphoma, and subcutaneous panniculitis-like T cell lympho-
mas have 100 % survival at a median of 2 years from enroll-
ment. There are early deaths, mostly from progressive disease,
in subjects with peripheral T cell (not otherwise specified),
NKT, and hepatosplenic T cell lymphomas.
Population-based data are very relevant to get a good idea
on the features of rare diseases, since centers will have a se-
lection of patients resulting in a certain bias. Strobbe et al. [14]
made use of such a database to describe nodular lymphocyte
predominant HL (NLPHL). A disadvantage of the use
population-based data is the longer period that patients need
to be collected, in this case 20 years, before meaningful con-
clusions can be taken and over time differences in criteria and
treatment occur. It was therefore important that at least the
pathology was reviewed. Seventy-three cases of NLPHLwere
analyzed with a median follow-up of 65 months (range 4–
257 months). Median age at diagnosis was 43 years (range
1–87), 85 % of the patients were male, B symptoms were
present in 6 %, and stage I/II disease was most common
(75 %). Patients were primarily treated with radiotherapy
(51 %), chemotherapy (26 %), combined modality (radiother-
apy and chemotherapy) (11 %), or surgical excision with care-
ful watch-and-wait (12 %). Relapses occurred in only seven
patients (10 %) after a median of 26 months (21–74 months).
Six patients (8 %) developed histologic transformation to
large cell lymphoma. Five patients (7 %) died during follow-
up due to progression of NLPHL (n=1), histologic transfor-
mation (n=2), and intercurrent deaths (n=2). The estimated
10-year overall survival was 94.0 % and the 10-year progres-
sion-free survival 76 %. A similar study was performed by
Kenderian et al. [15] with a focus on transformation, a larger
study, but from a center and even covering 40 years. Between
1970 and 2011, 222 consecutive adult patients with new un-
treated NLPHL were identified. Median age at diagnosis was
40 years and 146 (66 %) were males. The median follow-up
was 16 years. Seventeen patients (8 %) developed a
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transformation to DLBCL, exactly the same percentage as the
Strobbe study. The median time to transformation was
35 months (6–268). In a multivariate analysis, use of any prior
chemotherapy and splenic involvement were significantly as-
sociated with increased risk of transformation. The five-year
overall survival in those with transformed disease was 76 %
but transformation did not adversely affect overall survival.
Both studies confirm the distinct characteristics of NLPHL
with a good long-term prognosis. It is likely that it is possible
to reduce treatment intensity in early stage NLPHL without
affecting long-term outcome, which is especially relevant in
young individuals as is common in this disease.
Acquired C1-inhibitor (C1-INH) deficiency (C1-INH-
AAE) is a rare condition resulting in acquired angioedema
(AAE) and about 33 % of the patients develop NHL.
Castelli et al. [16] report the follow-up of 72 C1-INH-AAE
patients, followed for a median of 15 years. The median age
was 71 years with a median age at onset of angioedema symp-
toms was 58. Twenty patients were diagnosed with LG non-
follicular B-NHL (75 % were splenic MZL), one with FL and
MCL each and two with DLBCL. Fifteen NHLs were diag-
nosed at onset of AAE or thereafter (3 months to 7 years),
eight had already been diagnosed at onset of angioedema.
Two of 24 patients remain on watchful wait. Thirteen of 24
received chemotherapy; two received rituximab. Three
underwent splenectomy. All 18 patients receiving therapy
for NHL experienced post-treatment reduction in AAE symp-
toms. This study indicates that a clonal B cell proliferation is
underlying AAE in a major subset of patients and can lead to
production of C1-INH-neutralizing autoantibodies. The post-
germinal center origin of these B-NHLs suggests that immune
stimulation may contribute to the lymphomagenesis.
A subset of DLBCL is CD30 positive. Gong et al. [17]
studied 232 cases of de novo DLBCL in East China to inves-
tigate the prevalence and clinicopathological features of
CD30-positive DLBCL using a panel of immunohistochemi-
cal markers. Applying a >0% threshold (which is quite low in
my mind), CD30 was expressed in approximately 12 % of the
tumors from patients with Epstein-Barr virus (EBV) negative
DLBCL, affecting younger people and showing a lower fre-
quency of BCL2 expression and MYC/BCL2 co-expression.
Patients with CD30-positive DLBCLs showed better
progression-free survival and overall survival compared with
patients with CD30-negative DLBCLs.
Defining entities
B cell lymphomas
An interesting hypothesis was put forward in the previous
issue of the Journal of Hematopathology by van den Brand
et al. [18]: quite some cases that are diagnosed as FL but lack a
t(14;18)may actually be nodal(N)MZL. They studied 33 low-
grade B cell lymphomas without a BCL2 break and compared
the results with cases that had a BCL2 break. Follicular colo-
nization was noted in the lymphomas without a BCL2 rear-
rangement, which was strongly overlapping with the morpho-
logical features of NMZL. This study raises the hypothesis
that a subset of LG B-NHL with a follicular growth pattern
but without a BCL2 translocation actually represents NMZL.
Batlle-López et al. [19] used three immunohistochemical
approaches to separate GC from ABC-DLBCL on tissue mi-
croarrays (TMAs) with samples from 297 patients. In addi-
tion, they performed FISH forMYC, BCL2, IRF4, and BCL6.
Non-GC-DLBCL patients had significantly worse
progression-free survival and overall survival, based on all
three (Choi, Visco-Young, and Hans) algorithms, indicating
that any of these algorithms would be appropriate for identi-
fying patients who require alternative therapies to R-CHOP.
While MYC abnormalities had no impact on clinical outcome
in the non-GC subtype, patients with isolatedMYC rearrange-
ments and a GC-DLBCL phenotype had worse survival and
therefore might benefit from more aggressive treatment
approaches.
Lu et al. [20] approached the same issue and analyzed the
antibodies applied in the Hans algorithm and other genetic
factors in 601 DLBCL patients and the prognostic value of
the Hans algorithm in 306 cases who were treated with
chemoimmunotherapy. Patients with GC subtype indeed have
better overall survival and progression-free survival than non-
GC cases. However, CD10- and MUM1-positive cases and
cases that were negative for CD10, BCL6, andMUM, showed
different clinical characteristics and prognosis to others that
were assigned to the same cell-of-origin group, indicating that
the story is not complete, and calls for a consensus meeting on
the use of immunohistochemistry to determine DLBCL
subgroups.
Roth et al. [21] describe the flow cytometry results of
20 “double” or “triple” hit lymphomas (D/THL) with re-
current translocations involving MYC and BCL2 and/or
BCL. Most (89 %, 17/19) D/THL were CD10(+), 47 %
(9/19) lacked surface light chain, and a significant subset
had low expression of CD45 (47 %, 9/19), CD20 (42 %
8/19), and/or CD19 (39 %, 7/18), which did not vary by
genetic subgroup. However, compared to B-lymphoblastic
lymphoma (LBL), D/THL less frequently underexpressed
CD45 and CD20. Lower levels of BCL2 expression were
noted in the BCL6(+)/MYC(+) and BCL2(+)/BCL6(+
)/MYC(+) subgroups versus BCL2(+)/MYC(+) cases.
Dim CD45 expression correlated with inferior survival.
The authors conclude that although there is some overlap
with B-LBL, D/THL demonstrates a characteristic
immunophenotype which may have prognostic signifi-
cance. The data also show that flow cytometry cannot
replace genetic testing in these cases.
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Moench et al. [22] investigated the same tumor types and
report clinicopathologic features of 13 cases (nine DHL/four
THL). The median age was 59 years (range 30–74) and pa-
tients included eight females and five males. Presentation in-
cluded enlarging lymphadenopathy/masses (11 patients) and
abnormal peripheral blood findings (two patients). Features
which raised the differential of an immature neoplasm includ-
ed terminal deoxynucleotidyl transferase positivity (four
cases, two THL/two DHL); dim CD45 expression (seven
cases), lack of CD20 (two cases), or lack of surface immuno-
globulin light chain (three cases) by flow cytometry; and
blastoid morphology (two cases). They conclude that expres-
sion of TdT in a B cell lymphoma with mature features or
expression of surface light chain in a case otherwise sugges-
tive of B-lymphoblastic leukemia/lymphoma should initiate
investigations to exclude DHL/THL. This raises the question,
what is the optimal workup nowadays for a DLBCL, an issue
that can be addressed in the afore proposed consensus
meeting.
T cell lymphomas
Tanaka et al. [23] investigated the expression of TCRβ and
TCRγ protein expression of 42 gastrointestinal Tcell lympho-
mas. Nine (21 %) were positive for TCRγ protein expression
and five of these expressed TCRβ as well. TCRβ positivity
without TCRγ expression was seen in nine cases (21 %).
Twenty-four patients (57 %) were negative for both TCRβ
and γ. TCRγ cases were characterized by exclusive involve-
ment of intestinal sites (100 % vs. 11 %), but not of the stom-
ach (0 % vs. 78 %). Furthermore, TCRγ positivity was an
independent unfavorable prognostic factor. According to the
authors, this indicates that intestinal γδ T cell lymphoma con-
stitutes a distinct disease entity.
The splicing factor neuro-oncological ventral antigen 1
(NOVA1) is present in T cells of tertiary lymphoid structures.
Kim et al. [24] found that tumor cells of T and NK-cell lym-
phomas showed higher expression levels of NOVA1 than nor-
mal paracortical T cells, and 57 % of 177 T and NK-cell
lymphoma cases had diffuse and strong expression. The
NOVA1 expression level varied according to the subtype; it
was higher in angioimmunoblastic T cell lymphoma (AILT),
anaplastic lymphoma kinase (ALK)-negative anaplastic large
cell lymphoma (ALCL), and T-LBL, but it was lower in ALK-
positive ALCL. In almost all B cell lymphomas, NOVA1 ex-
pression was very low or negative. They conclude that upreg-
ulated NOVA1 expression seems to be a specific biological
feature of activated T cells and T and NK-cell lymphomas.
Dobashi et al. [25] investigated extranodal natural killer/T
cell lymphoma (ENKTL) for mutations in the JAK-STAT
pathway, recently reported in ENKTL cases. Targeted capture
sequencing of 602 cancer-related genes from 25 frozen
ENKTL samples revealed recurrent somatic mutations
involving BCOR (32 %), TP53 (16 %), DDX3X (12 %),
FAT4 (8 %), NRAS (8 %), MLL3 (12 %), and MIR17HG
(8 %). The pattern of BCOR aberrations (one nonsense and
five frame-shift mutations, a mutation leading to a splicing
error, and gene loss) suggested that loss of function of
BCOR was the functionally important outcome of such
changes. The literature was reviewed and the public data on
BCOR aberrations was reanalyzed and it was found that the
aberrations were frequently found in myeloid neoplasms, but,
interestingly, were highly specific to ENKTL among lym-
phoid malignancies. Given the high frequency and pattern of
aberration, BCOR is likely to play an important role in
ENKTL pathogenesis as a tumor suppressor gene.
Adult T cell leukemia/lymphoma (ATLL) is a rare T cell
neoplasm caused by human T cell leukemia virus type 1 oc-
curring in specific regions on the world. Tobayashi et al. [26]
analyzed 184 cases of peripheral T cell lymphoma, including
113 cases of ATLL for mutations in CCR4. These were pres-
ent in 27% (30/113) of cases of ATLL and 9 % (4/44) of cases
of peripheral T cell lymphoma not otherwise specified.
Identified mutations included nonsense (NS) and frame-shift
(FS) mutations. There were no differences in clinicopatholog-
ical features between ATLL cases with and without CCR4
mutation. All ATLL cases with CCR4 mutations expressed
CCR4 with higher CCR4 expression in cases with NS muta-
tions than in cases with wild-type (WT) CCR4. Furthermore,
among ATLL cases, FS mutation was associated with a poor
prognosis, compared with NSmutation andWTCCR4. These
results indicate that CCR4 mutation is an important determi-
nant of the clinical course in ATLL, and that NS and FS mu-
tations of CCR4 have a different effect in the pathogenesis.
Cutaneous lymphomas
Lee et al. [27] investigated clinical features of 52 primary and
secondary cutaneous ALCL. Although skin lesion character-
istics did not significantly differ between groups, the head and
neck location was more common in primary cutaneous
ALCL, whereas cutaneous lesion extent was greater in sec-
ondary cutaneous ALCL. Skin lesion extent in primary cuta-
neous ALCL was indicative of extracutaneous dissemination
development and skin lesion relapse. Neither ALK expression
nor clinical stage affected skin lesion characteristics in second-
ary cutaneous ALCL. Patients with primary cutaneous ALCL
demonstrated better survival outcomes. The skin lesion extent
and location on the leg were associated with a tendency to-
wards a poorer prognosis in primary cutaneous ALCL. The
secondary cutaneous ALCL prognosis was not influenced by
skin lesion characteristics.
The diagnosis of panniculitis-like T cell lymphoma
(SPTCL) can be difficult. Especially, cases of SPTCL and
lupus erythematosus panniculitis (LEP) can have clinical and
histopathologic overlap, raising the possibility that they
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represent opposite ends of a disease spectrum. SPTCL, how-
ever, is typically associated with greater morbidity and risk for
hemophagocytic lymphohistiocytosis (HLH). LeBlanc et al.
[28] present their experience regarding the histopathologic,
immunophenotypic, and molecular findings of 13 patients
with SPTCL and seven with LEP. Six SPTCL patients devel-
oped HLH, including two who were under the age of 21 years.
In the SPTCL group, 2 of 13 patients died of disease. In
contrast, there was no mortality or development of HLH in
the LEP cohort. With a limited panel (Ki-67, CD3, CD4, and
CD8 immunostains) foci of “Ki-67 hotspots” were present
among cytotoxic atypical CD8+ T cells in SPTCL. Ki-67
hotspots were not identified in LEP, thus aiding the distinction
of SPTCL from LEP. Lymphocyte atypia combined with ad-
ipocyte rimming of CD8+ T cells within Ki-67 hotspots was
also highly specific for the diagnosis of SPTCL. Hyaline
lipomembranous change, B cell aggregates, plasmacytoid
dendritic cell clusters, and plasma cell aggregates favored
the diagnosis of LEP but were identified in some cases of
SPTCL as well including patients with HLH. Especially the
Ki67 hot spots idea is new and can be helpful in this situation.
New entities/subtypes
Lorenzi et al. [29] report the clinical, morphological, pheno-
typical, and molecular features of three cases of a hitherto
unreported variant of Epstein-Barr virus (EBV)-positive, hu-
man herpes virus 8 (HHV8)-negative large B cell lymphoma
with exclusive intrafollicular localization. These cases oc-
curred in elderly individuals (63, 77, and 65 years old; one
male, two females) without obvious immune-deficiency, who
presented with high stage disease. The lymph nodes showed
an effaced nodular architecture with abnormal B cell follicles
colonized by EBV+ large, pleomorphic atypical cells, includ-
ing Reed-Sternberg-like cells, showing an activated B cell
phenotype (CD10-FOXP1-BCL6-IRF4+ or CD10-FOXP1+
BCL6+IRF4+) and intense expression of CD30. No monoclo-
nal light-chain restriction was detected by immunohistochem-
istry or in situ hybridization, and IGH rearrangement was
polyclonal; notably, EBV clonality was present in one case.
Lymphoma cells in all cases showed diffuse expression of the
Myc protein, while Bcl2 was dim or negative; moreover, the
strong expression of phosphorylated-STAT3 in tumor cell nu-
clei suggested activation of the JAK-STAT pathway. FISH
analysis was performed in two cases and showed no translo-
cations of BCL2, BCL6, MYC, and PAX5 genes. Response to
treatment was poor in 2/3 patients: one died after 18 months
and one is alive with disease after 12 months. This report on
intrafollicular EBV-positive large B cell lymphoma expands
the spectrum of EBV-associated lymphoproliferative disor-
ders in immunocompetent individuals.
Initially MYD88 mutations were seen as typical for
lymphoplasmacytic lymphoma (LPL) but the spectrum
has expanded. Rovira et al. [30] describe the incidence,
clinicopathological features, and outcome of 213 pa-
tients (115 M/98 F; median age, 65 years) with
DLBCL treated with immunochemotherapy in a single
institution with respect to MYD88 mutational status.
MYD88 mutations were found in 47 cases (22 %), in-
cluding L265P in 39 and S219C and M232F in four
cases, respectively. Patients with MYD88 L265P were
older, presenting frequent extranodal involvement, and
mostly corresponded to the ABC subtype. Five-year
overall survival for MYD88 wild-type, MYD88 L265P,
and other variants was 62, 52, and 75, respectively.
However, the prognostic impact was lost when the
ABC subtype was taken into account. The data are in
line with those from Taniguchi et al. [31] who analyzed
primary breast (PB)-DLBCL, which comprises <3 % of
extranodal lymphomas. It frequently reveals an ABC
phenotype and it has been reported to have gain-of-
function mutations in MYD88, CD79B, CARD11, and
TNFAIP3, resulting in constitutive activation of the NF-
kB pathway. Using Sanger sequencing on 46 breast
DLBCL cases, they found MYD88 L265P and CD79B
mutations in 27/46 (59 %) and 11/33 (33 %) cases,
respectively. Twenty-eight of 46 cases met the criteria
for PB-DLBCL. The frequency of MYD88 L265P and
CD79B mutations was 16/28 (57 %) and 9/23 (39 %),
respectively, in PB-DLBCL and 11/18 (61 %) and 2/10
(20 %), respectively, in the disseminated cases present-
ing in the breast, which might suggest that these belong
to the same disease entity.
Most of the post-transplant lymphoproliferative diseases
(PTLD) are EBV driven, but a subset is EBV negative.
Finalet Ferreiro et al. [32] performed array-comparative ge-
nome hybridization (aCGH) analysis of 21 EBV(+), 6
EBV(−) PTLD with morphology of DLBCL, and 11 control
DLBCL, and combined genomic data with their previously
published transcriptomic data. The analysis showed that
EBV(+) and EBV(−) cases have distinct aCGH profiles and
shared only one recurrent imbalance. EBV(−) displayed at
least ten aberrations recurrent in DLBCL, among which char-
acteristic gain of 3/3q and 18q, and loss of 6q23/TNFAIP3 as
well as 9p21/CDKN2A. The most prevalent aberration in
EBV(+) cases was gain/amplification of 9p24.1 targeting
PDCD1LG2/PDL2. These data indicate that the FOXP1 on-
cogene and the tumor suppressor CDKNA2 implicated in
EBV(−) DLBCL, do not play a role in the pathogenesis of
EBV(+) PT-DLBCL. Altogether, genomic profiling of PT-/
IC-DLBCL confirms that EBV(−) and EBV(+) PT-DLBCL
are distinct entities, while EBV(−) PT-DLBCL has features
in common with DLBCL, however EBV-positive DLBCL
outside the transplant setting were not included.
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Pitfalls in lymphoma diagnosis
As I wrote in my editorial [1], we know now that cells with
genetic alterations may occur in healthy individuals, and of
course these cells can expand to some extent. The border
between a benign expansion and a malignant process is there
probably impossible to define. A criterion we use in general is
expansion beyond the normal anatomical structure. It is there-
fore interesting to see what the consequences are of so-called
FL and MCL in situ (FLIS and MCLIS), because these are
accumulations of cells with a genetic alteration but still in their
normal microenvironment. Bermudez et al. [33] studied a se-
ries of 341 consecutive lymph node resection specimens from
patients diagnosed with colorectal (201 cases) and breast (140
cases) adenocarcinoma between 1998 and 2000. Incidental
and isolated FLIS was identified in 11/341 patients (3 %),
whereas incidental and isolated MCLIS was found in 2/341
patients (1 %). None of these patients developed overt lym-
phoma, which fits with the notion that these represent inciden-
tal findings for which probably the term lymphoma should be
avoided altogether. Next, a second series of five cases with
incidental and isolated FLIS was identified from consultation
files and also none of these patients developed overt lympho-
ma. Nybakken et al. [34] addressed a similar question, what is
the clinical meaning of the presence of isolated follicles that
exhibit atypical morphologic features? They collected seven
cases with centroblast-predominant isolated follicles and ab-
sent BCL2 staining in otherwise-normal lymph nodes. Four of
these showed a clonal B cell proliferation amid a polyclonal B
cell background (not so surprising, since germinal centers are
often (oligo)clonal) all cases lacked the IGH-BCL2 transloca-
tion and BCL2 protein expression. Although three patients
had invasive breast carcinoma at other sites, none were asso-
ciated with systemic lymphoma up to 44 months after diagno-
sis. This work also confirms the importance of architectural
changes when a diagnosis of lymphoma is considered. In line
with this is the work of van den Brand et al. [35] who present
an interesting case in which morphologically there was a FL,
but a part of the follicles was BCL2 negative and another part
was positive. They were able to demonstrate that both parts
belong to the same clone, but due to ongoing mutation, the
epitope recognized by the BCL2 antibody was lost in the
negative part of the lymphoma. All three articles show the
importance of combining morphology and immunophenotype
with genetics is important to come to a right diagnosis.
Jain et al. [36] incidentally found a case of ALK-
positive ALCL that stained for Napsin A, a marker often
used to classify a tumor a lung primary. They stained two
other cases from their archive and found the same result
and thus they conclude that ALK-positive DLBCL should
be considered in the differential diagnosis when evaluat-
ing a Napsin A-positive tumor of poorly differentiated
morphology and of unknown primary.
Prognostic factors in lymphoma
Ki-67 has been shown to be a good prognostic marker in
MCL. Hoster et al. [37] compared its value with other histo-
logical factors like tumor cell morphology and growth pattern
in more than 500 cases. Blastoid cytology was associated with
inferior survival but not independently of the Ki-67 index.
Growth pattern was not independently prognostic. Choi
et al. [38] determined semi quantitatively the level of CD20
expression in 48 cases of DLBCL and found a subgroup of the
patients with CD20 expression levels below the cut-off score
having poor clinical outcome. Yabe at al [39] evaluated 28
cases of hepatosplenic T cell lymphoma (HSTCL) patients
to determine factors that may be associated with outcome.
The HSTCL cells expressed γδ T cell receptor (TCR) in 20
(74 %), αβ TCR in five (19 %), and neither in two (7 %)
patients (one case not assessed). Serum bilirubin level
≥1.5 mg/dL, αβ TCR expression, and trisomy 8 each corre-
lated significantly with shorter survival.
All in all, the briefest paragraph on prognostic factors in the
series of review, you can read the argumentation in the previ-
ous issue [40].
Staging
Bone marrow biopsies are slowly being replaced by other
methods for staging. Cho et al. [41] investigated pretreatment
BM samples of 394 DLBCL patients with clonality testing in
addition to microscopic examination. Monoclonal immuno-
globulin gene rearrangement was detected in 25 % of cases.
Histologic B cell aggregates with the features of large B cell
lymphoma aggregates, small cell B cell lymphoma aggre-
gates, or B cell aggregates of unknown biological potential
were observed in 12 % of cases (7, 1, and 4 %, respectively).
Histologic B cell aggregates were more associated with
monoclonality than polyclonality. Cases with both
monoclonality and histologic B cell aggregates demonstrated
close association with poor prognostic factors such as a higher
International Prognostic Index score and showed an inferior
overall survival rate when compared to cases with only
monoclonality or only histologic B cell aggregates. From their
findings, a combination ofmonoclonality and histologic B cell
aggregates within the bone marrow was highly associated
with poor prognosis and could be used to determine high-
risk DLBLC patients with greater sensitivity and specificity
than conventional microscopic examination or immunoglob-
ulin gene rearrangement study alone. A combination with
clonality testing in the primary tumor would have been help-
ful, and a two-step approach might be sensible: only clonality
testing in equivocal cases; however, the value of that approach
needs to be determined.
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Di Martino et al. [42] compared the levels of BCL-1/JH
fusion products detected by q-PCR in the concurrent periph-
eral blood (PB) and bone marrow (BM) aspirate samples from
seven patients with MCL. In patients with moderate to high
levels of BCL-1/JH copies, the results of q-PCR analysis of
PB and BM aspirate samples correlate well. In patients with
high levels of BCL-1/JH copies, instead, PB levels are a good
indication of tumor burden. Finally, in patients with low levels
of BCL-1/JH copies, the t(11;14) may be detected by identi-
fication of neoplastic cells. They conclude that their data sug-
gest that PB can be reliably used in place of BM aspirate both
for detection of translocation status during minimal residual
disease monitoring and for a possible molecular relapse, espe-
cially in those patients who have moderate to high levels of
BCL-1/JH copies. If these results will be confirmed on a wider
number of MCL patients (seven is indeed very few!!), this
might be a promising approach.
Ancillary techniques
Sometimes a complete new technique that is simple but really
different comes up and it is interesting to see if the promise
becomes real (remember AGNORs…..). Aesif et al. [43] de-
scribe a method that separates benign from malignant cells, a
holy grail in pathology of course. They developed a staining
technique that enables visualization of tissue thiols in situ
using bright field microscopy and validated it using gastroin-
testinal tissue specimens. They used this technique to assess
benign tonsillectomy and DLBCL. Tonsillectomy specimens
exhibited diffuse presence of free thiols. Staining for revers-
ibly oxidized thiols was confined to germinal center macro-
phages and sinus histiocytes. DLBCL was strongly positive
for free thiols within malignant cells. Finally, in contrast to
benign B cells, the malignant cells demonstrated pronounced
and diffuse staining for reversibly oxidized thiols, according
to the authors, they demonstrated intrinsic differences between
benign and malignant cells. I am curious to read the follow-up
studies.
It is now well demonstrated that free circulating DNA is
partially derived from neoplastic cells and contains at least
part of the genetic alterations present in the tumor. Camus
et al. [44] developed digital PCR (dPCR) assays for the detec-
tion of exportin-1 (XPO1) E571K, EZH2 Y641N, and
MYD88 L265P mutations in DLBCL patients, in order to
identify patients most likely to benefit from targeted
therapies. They demonstrated that these dPCR assays were
sufficiently sensitive to detect rare XPO1, EZH2, and
MYD88 mutations in plasma cfDNA, with a sensitivity of
0.05 %. This is therefore a promising technique for the man-
agement of DLBCL.
Lee et al. [45] used the BIOMED-2 multiplex polymerase
chain reaction (PCR) assay in 27 patients using formalin-fixed
paraffin-embedded tissues, with subsequent cloning and se-
quencing of the amplified Ig genes in 17 patients. All 27 cases
of primary and corresponding relapsed tumors showed mono-
clonal rearrangements of the Ig genes. Whereas IgVH or
IgVK fragment lengths were identical in 8/27 pairs (30 %),
fragment lengths differed in 19/27 pairs (70 %). In 17 cases
analyzed by sequencing, an identical VDJ gene rearrangement
was confirmed in 4/4 pairs (100 %) with the same fragment
lengths and in 10/13 pairs (77 %) with different fragment
lengths. Four of 17 primary lymphomas had multiple VDJ
rearrangements, and three of them showed an unrelated re-
lapse. Unrelated relapse was observed in 1/8 mantle cell lym-
phomas, 1/5 diffuse large B cell lymphomas, and a large B cell
lymphoma developed in a patient with a small lymphocytic
lymphoma. Unrelated relapses developed after a longer
disease-free interval and tended to show poorer outcome com-
pared with related relapse. In summary, relapse of a lympho-
ma from an unrelated clone is uncommon, but can occur in B
cell lymphomas. Clonal relationships should be determined by
sequencing of the Ig genes, and not just by comparing the
PCR product size. However, according to Jiang et al. [46],
the situation is more complicated than that. They created a
VDJ-sequencing protocol to trace the clonal evolution pat-
terns of DLBCL relapse by exploiting VDJ recombination
and somatic hypermutation (SHM), two unique features of B
cell lymphomas. When applying this analysis to several
diagnosis-relapse pairs, they discovered key evidence that
multiple distinctive tumor evolutionary patterns could lead
to DLBCL relapse, obviously an area that needs further
investigations.
Dubois et al. [47] describe their approach to determine
targets for treatment in lymphomas. Their “Lymphopanel”
was designed to identify mutations in 34 genes, selected ac-
cording to literature data and a whole exome sequencing study
of relapsed/refractory DLBCL patients. The tumor DNA of
215 patients with CD20+ de novo DLBCL was used and
was informative for 96 % of patients. A clear depiction of
DLBCL subtype molecular heterogeneity was uncovered with
the Lymphopanel, confirming that ABC, GC, and primary
mediastinal B cell lymphoma (PMBL) are frequently affected
by mutations in NF-kB, epigenetic, and JAK-STAT pathways,
respectively. Novel truncating immunity pathway, ITPKB,
MFHAS1, and XPO1 mutations were identified as highly
enriched in PMBL. Notably, TNFAIP3 and GNA13mutations
in ABC patients treated with R-CHOP were associated with
significantly less favorable prognoses. Although this is a very
relevant approach, the search for more functional methods to
assess sensitivity for specific drugs is badly needed. Chapuy
et al. [48] generated and characterized a panel of DLBCL
patient-derived xenograft (PDX) models including eight that
reflect the immunophenotypic, transcriptional, genetic, and
functional heterogeneity of primary DLBCL and one that is
a plasmablastic lymphoma. Six of the eight DLBCL models
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were ABC-type tumors that exhibited ABC-associated muta-
tions such as MYD88, CD79B, CARD11, and PIM1. The
remaining two DLBCL PDX models were GCB-type, with
characteristic alterations of GNA13, CREBBP, and EZH2,
and chromosomal translocations involving IgH and either
BCL2 or MYC. Only 25 % (2/8) of the DLBCL PDX models
harbored inactivating TP53 mutations whereas 75 % (6/8) of
tumors exhibited copy number alterations of TP53 or its up-
stream modifier, CDKN2A, consistent with the reported inci-
dence and type of p53 pathway alterations in primary
DLBCL. By CCC criteria, 6/8 DLBCL PDX models were
BCR-type tumors that exhibited selective sIg expression and
sensitivity to entospletinib, a recently developed SYK inhibi-
tor. Thus, this group has established and characterized PDX
models of DLBCL and demonstrated their usefulness in func-
tional analyses of proximal BCR pathway inhibition.
Gene alterations are important, but proteins do the work.
Wu et al. [49] applied two dimensional gel electrophoresis to
compare seven GC NHL cell lines with a lymphoblastoid cell
line (LCL). An average of 130 spots was at least two folds
different in intensity between NHL cell lines and the LCL.
They selected approximately 38 protein spots per NHL cell
line and linked them to 145 unique spots based on the location
in the gel. Thirty-four spots that were found altered in at least
three NHL cell lines when compared to LCL were submitted
for mass spectography. This resulted in 28 unique proteins, a
substantial proportion of these proteins were involved in cell
motility and cell metabolism. Loss of expression of B2M and
gain of expression of PRDX1 and PPIAwas confirmed in the
cell lines and in primary lymphoma tissue. Moreover, inhibi-
tion of PPIA with cyclosporine A blocked cell growth of the
cell lines. This is therefore a promising new approach.
And finally, stop grading FL by eye, use FLAGS [50]!
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